Exact Mass: 556.278452
Exact Mass Matches: 556.278452
Found 500 metabolites which its exact mass value is equals to given mass value 556.278452,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Cucurbitacin_E
Cucurbitacin E is a cucurbitacin in which a lanostane skeleton is multi-substituted with hydroxy, methyl and oxo substituents, with unsaturation at positions 1, 5 and 23. It is a cucurbitacin and a tertiary alpha-hydroxy ketone. Cucurbitacin E is a natural product found in Cucurbita foetidissima, Helicteres angustifolia, and other organisms with data available. A cucurbitacin in which a lanostane skeleton is multi-substituted with hydroxy, methyl and oxo substituents, with unsaturation at positions 1, 5 and 23. Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex. Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.
RD4-2174
Ingenol 3,20-dibenzoate is a benzoate ester. Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells[1][2]. Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells[1][2].
Dipiperamide C
C33H36N2O6 (556.2573236000001)
Dipiperamide C is found in herbs and spices. Dipiperamide C is an alkaloid from white pepper, Piper nigrum. Alkaloid from white pepper, Piper nigrum. Dipiperamide C is found in herbs and spices.
Cucurbitacin E
Dronedarone
C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii > C01BD - Antiarrhythmics, class iii C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone is a substrate for and a moderate inhibitor of CYP3A4[1].
Omadacycline
Pexmetinib
PA(2:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))
PA(2:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/2:0)
PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/2:0), in particular, consists of one chain of one Resolvin D5 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))
PA(2:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Protectin DX at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/2:0)
PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/2:0), in particular, consists of one chain of one Protectin DX at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Iryantherin G
Iryantherin H
Dronedarone
C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii > C01BD - Antiarrhythmics, class iii C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents CONFIDENCE standard compound; INTERNAL_ID 2181 CONFIDENCE standard compound; EAWAG_UCHEM_ID 2855 INTERNAL_ID 2181; CONFIDENCE standard compound Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone is a substrate for and a moderate inhibitor of CYP3A4[1].
Cucurbitacin E
Cucurbitacin e is a member of the class of compounds known as cucurbitacins. Cucurbitacins are polycyclic compounds containing the tetracyclic cucurbitane nucleus skeleton, 19-(10->9b)-abeo-10alanost-5-ene (also known as 9b-methyl-19-nor lanosta-5-ene), with a variety of oxygenation functionalities at different positions. Cucurbitacin e is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Cucurbitacin e is a bitter tasting compound found in cucumber, muskmelon, and watermelon, which makes cucurbitacin e a potential biomarker for the consumption of these food products. Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex. Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.
6,9-Dihydroxymegastigm-7-en-3-one 9-O-beta-D-glucopyranoside tetraacetate
(4R)-4-(3,4-dihydroxy-6-{(2S,4R,6S)-4-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-6-pentyl[1,3]dioxan-2-yl}-2-methylbenzyl)-4,5-dihydro-5,5-dimethylfuran-2(3H)-one|lycifuranone C
12-O-(2E,4E-decadienoyl)-4-deoxy-16-hydroxyphorbol-13-acetate
5beta,6beta-epoxy-4beta-hydroxy-27-(1-formyloxy-1-methylethoxy)-1-oxo-witha-2,24-dienolide
5alpha,13alpha,15beta-trihydroxy-16beta-methoxyl-1alpha,6alpha,7beta-triacetoxy-12-oxocassane-14,16-epoxy|neocaesalpin AE
methyl-2-hydroxy-3beta-isobutyroxy-1-oxomeliac-8(30)-enate
[2-(2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-8,10,12,15,16,17-hexahydro-7H-cyclopenta[a]phenanthren-17-yl)-6-hydroxy-6-methyl-3-oxohept-4-en-2-yl] acetate
6beta-acetoxy-7beta-hydroxy-8,13-epoxy-labd-14-en-11-one-1alpha-O-beta-glucopyranoside|forskoditerpenoside C
C32H44O8_Estra-1,5-diene-3,11-dione, 17-[(1R,3E)-1-(acetyloxy)-5-hydroxy-1,5-dimethyl-2-oxo-3-hexen-1-yl]-2,16-dihydroxy-4,4,9,14-tetramethyl-, (9beta,10alpha,16alpha,17beta)
Asp Phe Ile Tyr
Asp Phe Leu Tyr
Asp Phe Tyr Ile
Asp Phe Tyr Leu
Asp Ile Phe Tyr
Asp Ile Tyr Phe
Asp Leu Phe Tyr
Asp Leu Tyr Phe
Asp Tyr Phe Ile
Asp Tyr Phe Leu
Asp Tyr Ile Phe
Asp Tyr Leu Phe
Glu Phe Val Tyr
Glu Phe Tyr Val
Glu Pro Arg Arg
Glu Arg Pro Arg
Glu Arg Arg Pro
Glu Val Phe Tyr
Glu Val Tyr Phe
Glu Tyr Phe Val
Glu Tyr Val Phe
Phe Asp Ile Tyr
Phe Asp Leu Tyr
Phe Asp Tyr Ile
Phe Asp Tyr Leu
Phe Glu Val Tyr
Phe Glu Tyr Val
Phe Phe Phe Pro
Phe Phe Ile Met
Phe Phe Leu Met
Phe Phe Met Ile
Phe Phe Met Leu
Phe Phe Pro Phe
Phe Ile Asp Tyr
Phe Ile Phe Met
Phe Ile Met Phe
Phe Ile Tyr Asp
Phe Leu Asp Tyr
Phe Leu Phe Met
Phe Leu Met Phe
Phe Leu Tyr Asp
Phe Met Phe Ile
Phe Met Phe Leu
Phe Met Ile Phe
Phe Met Leu Phe
Phe Pro Phe Phe
Phe Val Glu Tyr
Phe Val Tyr Glu
Phe Tyr Asp Ile
Phe Tyr Asp Leu
Phe Tyr Glu Val
Phe Tyr Ile Asp
Phe Tyr Leu Asp
Phe Tyr Val Glu
His His Thr Tyr
C25H32N8O7 (556.2393841999999)
His His Tyr Thr
C25H32N8O7 (556.2393841999999)
His Lys Ser Trp
His Lys Trp Ser
His Met Asn Arg
C21H36N10O6S (556.2539876000001)
His Met Arg Asn
C21H36N10O6S (556.2539876000001)
His Asn Met Arg
C21H36N10O6S (556.2539876000001)
His Asn Arg Met
C21H36N10O6S (556.2539876000001)
His Asn Thr Trp
C25H32N8O7 (556.2393841999999)
His Asn Trp Thr
C25H32N8O7 (556.2393841999999)
His Gln Ser Trp
C25H32N8O7 (556.2393841999999)
His Gln Trp Ser
C25H32N8O7 (556.2393841999999)
His Arg Met Asn
C21H36N10O6S (556.2539876000001)
His Arg Asn Met
C21H36N10O6S (556.2539876000001)
His Ser Lys Trp
His Ser Gln Trp
C25H32N8O7 (556.2393841999999)
His Ser Trp Lys
His Ser Trp Gln
C25H32N8O7 (556.2393841999999)
His Thr His Tyr
C25H32N8O7 (556.2393841999999)
His Thr Asn Trp
C25H32N8O7 (556.2393841999999)
His Thr Trp Asn
C25H32N8O7 (556.2393841999999)
His Thr Tyr His
C25H32N8O7 (556.2393841999999)
His Trp Lys Ser
His Trp Asn Thr
C25H32N8O7 (556.2393841999999)
His Trp Gln Ser
C25H32N8O7 (556.2393841999999)
His Trp Ser Lys
His Trp Ser Gln
C25H32N8O7 (556.2393841999999)
His Trp Thr Asn
C25H32N8O7 (556.2393841999999)
His Tyr His Thr
C25H32N8O7 (556.2393841999999)
His Tyr Thr His
C25H32N8O7 (556.2393841999999)
Ile Asp Phe Tyr
Ile Asp Tyr Phe
Ile Phe Asp Tyr
Ile Phe Phe Met
Ile Phe Met Phe
Ile Phe Tyr Asp
Ile Met Phe Phe
Ile Val Tyr Tyr
Ile Tyr Asp Phe
Ile Tyr Phe Asp
Ile Tyr Val Tyr
Ile Tyr Tyr Val
Lys His Ser Trp
Lys His Trp Ser
Lys Ser His Trp
Lys Ser Trp His
Lys Trp His Ser
Lys Trp Ser His
Leu Asp Phe Tyr
Leu Asp Tyr Phe
Leu Phe Asp Tyr
Leu Phe Phe Met
Leu Phe Met Phe
Leu Phe Tyr Asp
Leu Met Phe Phe
Leu Val Tyr Tyr
Leu Tyr Asp Phe
Leu Tyr Phe Asp
Leu Tyr Val Tyr
Leu Tyr Tyr Val
Met Phe Phe Ile
Met Phe Phe Leu
Met Phe Ile Phe
Met Phe Leu Phe
Met His Asn Arg
C21H36N10O6S (556.2539876000001)
Met His Arg Asn
C21H36N10O6S (556.2539876000001)
Met Ile Phe Phe
Met Leu Phe Phe
Met Asn His Arg
C21H36N10O6S (556.2539876000001)
Met Asn Arg His
C21H36N10O6S (556.2539876000001)
Met Arg His Asn
C21H36N10O6S (556.2539876000001)
Met Arg Asn His
C21H36N10O6S (556.2539876000001)
Asn His Met Arg
C21H36N10O6S (556.2539876000001)
Asn His Arg Met
C21H36N10O6S (556.2539876000001)
Asn His Thr Trp
C25H32N8O7 (556.2393841999999)
Asn His Trp Thr
C25H32N8O7 (556.2393841999999)
Asn Met His Arg
C21H36N10O6S (556.2539876000001)
Asn Met Arg His
C21H36N10O6S (556.2539876000001)
Asn Arg His Met
C21H36N10O6S (556.2539876000001)
Asn Arg Met His
C21H36N10O6S (556.2539876000001)
Asn Thr His Trp
C25H32N8O7 (556.2393841999999)
Asn Thr Trp His
C25H32N8O7 (556.2393841999999)
Asn Trp His Thr
C25H32N8O7 (556.2393841999999)
Asn Trp Thr His
C25H32N8O7 (556.2393841999999)
Pro Glu Arg Arg
Pro Phe Phe Phe
Pro Arg Glu Arg
Pro Arg Arg Glu
Pro Arg Val Trp
Pro Arg Trp Val
Pro Val Arg Trp
Pro Val Trp Arg
Pro Trp Arg Val
Pro Trp Val Arg
Gln His Ser Trp
C25H32N8O7 (556.2393841999999)
Gln His Trp Ser
C25H32N8O7 (556.2393841999999)
Gln Ser His Trp
C25H32N8O7 (556.2393841999999)
Arg Glu Pro Arg
Arg Glu Arg Pro
Arg His Met Asn
C21H36N10O6S (556.2539876000001)
Arg His Asn Met
C21H36N10O6S (556.2539876000001)
Arg Met His Asn
C21H36N10O6S (556.2539876000001)
Arg Met Asn His
C21H36N10O6S (556.2539876000001)
Arg Asn His Met
C21H36N10O6S (556.2539876000001)
Arg Asn Met His
C21H36N10O6S (556.2539876000001)
Arg Pro Glu Arg
Arg Pro Arg Glu
Arg Pro Val Trp
Arg Pro Trp Val
Arg Arg Glu Pro
Arg Arg Pro Glu
Arg Val Pro Trp
Arg Val Trp Pro
Arg Trp Pro Val
Arg Trp Val Pro
Ser His Lys Trp
Ser His Trp Lys
Ser Lys His Trp
Ser Lys Trp His
Ser Trp His Lys
Ser Trp Lys His
Val Glu Phe Tyr
Val Glu Tyr Phe
Val Phe Glu Tyr
Val Phe Tyr Glu
Val Ile Tyr Tyr
Val Leu Tyr Tyr
Val Pro Arg Trp
Val Pro Trp Arg
Val Arg Pro Trp
Val Arg Trp Pro
Val Trp Pro Arg
Val Trp Arg Pro
Val Tyr Glu Phe
Val Tyr Phe Glu
Val Tyr Ile Tyr
Val Tyr Leu Tyr
Val Tyr Tyr Ile
Val Tyr Tyr Leu
Trp His Lys Ser
Trp His Ser Lys
Trp Lys His Ser
Trp Lys Ser His
Trp Pro Arg Val
Trp Pro Val Arg
Trp Arg Pro Val
Trp Arg Val Pro
Trp Ser His Lys
Trp Ser Lys His
Trp Val Pro Arg
Trp Val Arg Pro
Tyr Asp Phe Ile
Tyr Asp Phe Leu
Tyr Asp Ile Phe
Tyr Asp Leu Phe
Tyr Glu Phe Val
Tyr Glu Val Phe
Tyr Phe Asp Ile
Tyr Phe Asp Leu
Tyr Phe Glu Val
Tyr Phe Ile Asp
Tyr Phe Leu Asp
Tyr Phe Val Glu
Tyr Ile Asp Phe
Tyr Ile Phe Asp
Tyr Ile Val Tyr
Tyr Ile Tyr Val
Tyr Leu Asp Phe
Tyr Leu Phe Asp
Tyr Leu Val Tyr
Tyr Leu Tyr Val
Tyr Val Glu Phe
Tyr Val Phe Glu
Tyr Val Ile Tyr
Tyr Val Leu Tyr
Tyr Val Tyr Ile
Tyr Val Tyr Leu
Tyr Tyr Ile Val
Tyr Tyr Leu Val
Tyr Tyr Val Ile
Tyr Tyr Val Leu
PG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)
Dipiperamide C
C33H36N2O6 (556.2573236000001)
4-methoxyphenyl 2,4,6-tri-o-benzyl-beta-d-galactopyranoside
9,9-Dimethyl-N,N-bis(3-methylphenyl)-N,N-diphenyl-9H-fluorene-2,7-diamine
4-Methoxyphenyl 2,3,6-Tri-O-benzyl-beta-D-galactopyranoside
Omadacycline
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01A - Tetracyclines > J01AA - Tetracyclines C254 - Anti-Infective Agent > C258 - Antibiotic
1H-1-Benzazepine-1-acetic acid, 3-(((1-((2R)-2-carboxy-4-(1-naphthalenyl)butyl)cyclopentyl)carbonyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (3S)-
C33H36N2O6 (556.2573236000001)
Pexmetinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
Forskoditerpenoside C
A diterpene glycoside that is labd-14-en-11-one substituted by beta-acetoxy group at position 6, an epoxy group between positions 8 and 13, a beta-hydroxy group at position 7 and a beta-D-glucopyranosyloxy group at position 1 (the 1alpha stereoisomer). Isolated from the whole plant of Coleus forskohlii, it shows relaxative effects on isolated guinea pig tracheal spirals in vitro.
(4S,4aS,5aR,12aR)-2-carbamoyl-7-(dimethylamino)-4-(dimethylazaniumyl)-9-[(2,2-dimethylpropylamino)methyl]-10,11,12a-trihydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracen-1-olate
[(E)-6-[(9R,13R,14S,16R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-8,10,12,15,16,17-hexahydro-7H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate
rel-12-O-(4Z,7Z)-Deca-4,7-dienoylphorbol-13-acetate
A natural product found in Pimelea elongata.
2-[(4-Acetylamino-phenyl)-(2-benzotriazol-1-yl-acetyl)-amino]-2-(4-methoxy-phenyl)-N-(tetrahydro-furan-2-ylmethyl)-acetamide
4-[(1R)-1-phenoxyethyl]-5-[5-[(1R)-1-phenoxyethyl]-3-(phenylmethyl)-4-triazolyl]-1-(phenylmethyl)triazole
N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4,4,4-trifluorobutanamide
(1R)-N-(2-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-2-(1-oxo-2-phenylethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
[(1R)-2-[(3,5-dimethoxyphenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-(3-pyridinyl)methanone
4-[3-[(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-(piperidine-1-carbonyl)-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]benzonitrile
1-[[(2R,3S)-8-(3-fluorophenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
3-[3-[(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-(piperidine-1-carbonyl)-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]benzonitrile
4-[3-[(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-[oxo(1-piperidinyl)methyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]benzonitrile
N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4,4,4-trifluorobutanamide
3-[3-[(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-6-[oxo(1-piperidinyl)methyl]-1,3-dihydropyrrolo[3,4-c]pyridin-4-yl]phenyl]benzonitrile
N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4,4,4-trifluorobutanamide
N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4,4,4-trifluorobutanamide
N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4,4,4-trifluorobutanamide
N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4,4,4-trifluorobutanamide
(1S)-N-(2-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-2-(1-oxo-2-phenylethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-pentadec-9-enoate
(1-octanoyloxy-3-phosphonooxypropan-2-yl) (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
(1-hexanoyloxy-3-phosphonooxypropan-2-yl) (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
(1-butanoyloxy-3-phosphonooxypropan-2-yl) (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
(1-acetyloxy-3-phosphonooxypropan-2-yl) (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
(1-decanoyloxy-3-phosphonooxypropan-2-yl) (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
[(E,6R)-6-[(8S,9R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-8,10,12,15,16,17-hexahydro-7H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate
(1-decanoyloxy-3-phosphonooxypropan-2-yl) (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate
[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-phosphonooxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate
[1-[(E)-dec-4-enoyl]oxy-3-phosphonooxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate
2-[[3-acetyloxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
1-(1Z-hexadecenyl)-glycero-3-phospho-(1-myo-inositol)
1-(9Z-pentadecenoyl)-glycero-3-phospho-(1-myo-inositol)
(3as,5ar,9r,10as)-9-(benzoyloxy)-8-[(benzoyloxy)methyl]-1-isopropyl-5a-methyl-6-oxo-2h,3h,4h,5h,9h,10h,10ah-cyclohepta[e]indene-3a-carboxylic acid
2-methyl-5-oxooxolan-3-yl (2r,3s,6s,7s,9r)-2-[(2s,5s)-5-(3-hydroxyphenyl)-5-methoxypentan-2-yl]-3,9,11,11-tetramethyl-8-oxo-1-oxaspiro[5.5]undec-4-ene-7-carboxylate
(3e,6s)-6-[(1r,2r,3as,3bs,9as,9br,11ar)-2,8-dihydroxy-3a,6,6,9b,11a-pentamethyl-7,10-dioxo-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate
(1s,2r,4r,5r,9r,10r,13r,14r,15s,17r)-9-(furan-3-yl)-15-(2-methoxy-2-oxoethyl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl 2-methylpropanoate
6-(furan-3-yl)-16-(1-hydroxy-2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl 2-methylpropanoate
3-hydroxy-3',3a,4'',6,6,9a,11a-heptamethyl-5'',7,10-trioxo-2,3,4,5,5a,8,9,11-octahydrodispiro[cyclopenta[a]phenanthrene-1,2':5',2''-bis(oxolane)]-4-yl acetate
17-ethyl-6,21-dihydroxy-19-[1-(1h-indol-3-yl)ethyl]-7,9,16-trimethyl-15-oxa-20-azatetracyclo[11.8.0.0¹,¹⁸.0¹⁴,¹⁶]henicosa-3,7,11,20-tetraene-2,5-dione
(1s,3z,6r,7z,9s,11z,13r,14s,16r,17s,18r,19s)-17-ethyl-6,21-dihydroxy-19-[(1r)-1-(1h-indol-3-yl)ethyl]-7,9,16-trimethyl-15-oxa-20-azatetracyclo[11.8.0.0¹,¹⁸.0¹⁴,¹⁶]henicosa-3,7,11,20-tetraene-2,5-dione
(4r)-4-({3,4-dihydroxy-6-[(2s,4r,6s)-4-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-6-pentyl-1,3-dioxan-2-yl]-2-methylphenyl}methyl)-5,5-dimethyloxolan-2-one
(1r,5r,6r,13r,14s,16s)-6-(furan-3-yl)-13-hydroxy-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl 2-methylpropanoate
(3e,6s)-6-[(1r,2r,3as,3bs,9ar,9br,11ar)-2,8-dihydroxy-3a,6,6,9b,11a-pentamethyl-7,10-dioxo-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate
2alpha-benzoyloxy-9alpha,10beta-diacetoxy-1beta,5alpha,13alpha-trihydroxy-4(20),11-taxadiene
{"Ingredient_id": "HBIN005279","Ingredient_name": "2alpha-benzoyloxy-9alpha,10beta-diacetoxy-1beta,5alpha,13alpha-trihydroxy-4(20),11-taxadiene","Alias": "2\u03b1-benzoyloxy-9\u03b1,10\u03b2-diacetoxy-1\u03b2,5\u03b1,13\u03b1-trihydroxy-4(20),11-taxadiene","Ingredient_formula": "C31H40O9","Ingredient_Smile": "CC1=C2C(C(C3(CCC(C(=C)C3C(C(C2(C)C)(CC1O)O)OC(=O)C4=CC=CC=C4)O)C)OC(=O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "25197;2255","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
artocommunol cb
{"Ingredient_id": "HBIN016981","Ingredient_name": "artocommunol cb","Alias": "NA","Ingredient_formula": "C35H40O6","Ingredient_Smile": "CC(=CCCC(=CCC1=C(OC2=C3C=CC(OC3=C(C(=C2C1=O)O)CC=C(C)C)(C)C)C4=C(C=C(C=C4)O)O)C)C","Ingredient_weight": "556.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1811","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "639645","DrugBank_id": "NA"}
(1s,3s,3'r,3as,4s,4''s,5's,5ar,9as,11as)-3-hydroxy-3',3a,4'',6,6,9a,11a-heptamethyl-5'',7,10-trioxo-2,3,4,5,5a,8,9,11-octahydrodispiro[cyclopenta[a]phenanthrene-1,2':5',2''-bis(oxolane)]-4-yl acetate
2-methyl-5-oxooxolan-3-yl 2-[5-(3-hydroxyphenyl)-5-methoxypentan-2-yl]-3,9,11,11-tetramethyl-8-oxo-1-oxaspiro[5.5]undec-4-ene-7-carboxylate
6-(furan-3-yl)-13-hydroxy-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl 2-methylpropanoate
1-{3-[(1r,2s,3r)-1,4-bis(4-hydroxyphenyl)-2,3-dimethylbutyl]-2,4,6-trihydroxyphenyl}-3-(4-methoxyphenyl)propan-1-one
[(2s,3s,4s,5r,6s)-6-[(2r)-3-(hexadecanoyloxy)-2-hydroxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid
(1r,7e,9s,11e,13r,14s,16r,17s,18r,19s)-17-ethyl-21-hydroxy-19-[(1r)-1-(1h-indol-3-yl)ethyl]-7,9,16-trimethyl-15-oxa-20-azatetracyclo[11.8.0.0¹,¹⁸.0¹⁴,¹⁶]henicosa-7,11,20-triene-2,5,6-trione
methyl 2-[(1r,2s,3s)-2-[(1r,5s,6r,7r,7as)-6,7-bis(acetyloxy)-1-(furan-3-yl)-7a-methyl-4-methylidene-2,5,6,7-tetrahydro-1h-inden-5-yl]-3-hydroxy-2,6,6-trimethyl-5-oxocyclohexyl]acetate
1-[(1s,2r,3r,4s)-2,3-bis[(1e)-2-(2h-1,3-benzodioxol-5-yl)ethenyl]-4-(pyrrolidine-1-carbonyl)cyclobutanecarbonyl]piperidine
C33H36N2O6 (556.2573236000001)
11-[(benzoyloxy)methyl]-5,6-dihydroxy-3,7,11,14-tetramethyl-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-4-yl benzoate
(1s,3e,6r,7e,9s,11e,13r,14s,16r,17s,18r,19s)-17-ethyl-6,21-dihydroxy-19-[(1r)-1-(1h-indol-3-yl)ethyl]-7,9,16-trimethyl-15-oxa-20-azatetracyclo[11.8.0.0¹,¹⁸.0¹⁴,¹⁶]henicosa-3,7,11,20-tetraene-2,5-dione
2-[(2-{[(3-{3,4-dihydroxy-5-[1-(c-hydroxycarbonimidoyl)-2-iminoimidazolidin-4-yl]pentyl}-5-hydroxy-6-methyl-1,2,3,6-tetrahydropyrazin-2-yl)(hydroxy)methylidene]amino}-1-hydroxypropylidene)amino]-3-methylbutanoic acid
C23H40N8O8 (556.2968960000001)
methyl 6-[(8-hydroxy-2,6-dimethylocta-2,6-dienoyl)oxy]-7-methyl-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-carboxylate
6-{2,8-dihydroxy-3a,6,6,9b,11a-pentamethyl-7,10-dioxo-1h,2h,3h,3bh,5ah,9ah,11h-cyclopenta[a]phenanthren-1-yl}-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate
(3as,5ar,9r,10ar)-9-(benzoyloxy)-8-[(benzoyloxy)methyl]-1-isopropyl-5a-methyl-6-oxo-2h,3h,4h,5h,9h,10h,10ah-cyclohepta[e]indene-3a-carboxylic acid
16-hydroxy-4,15-dimethoxy-2,6,14,17-tetramethyl-11-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-3-one
(1r,3br,4s,5r,5as,7r,9s,9ar,9br,11as)-4,7-bis(acetyloxy)-1-(furan-3-yl)-9-hydroxy-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate
1-{5',13',25'-trimethyl-11',22'-dioxo-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraen-17'-yl}ethyl acetate
(1r,2s,4r,5r,6r,7r,10s,11s,14s,16r)-5-(acetyloxy)-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl 1-methyl butanedioate
(2r,4s,5r,9r,10r,13r,14s,15s,17r)-9-(furan-3-yl)-15-(2-methoxy-2-oxoethyl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl 2-methylpropanoate
12,14-bis(acetyloxy)-6-(furan-3-yl)-1,7,11,15,15-pentamethyl-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-18-yl acetate
2-(2,4-dihydroxyphenyl)-3-(3,7-dimethylocta-2,6-dien-1-yl)-5-hydroxy-8,8-dimethyl-6-(3-methylbut-2-en-1-yl)pyrano[2,3-h]chromen-4-one
methyl 2-{2-[6,7-bis(acetyloxy)-1-(furan-3-yl)-7a-methyl-4-methylidene-2,5,6,7-tetrahydro-1h-inden-5-yl]-3-hydroxy-2,6,6-trimethyl-5-oxocyclohexyl}acetate
2-[(1-hydroxy-2-{[1-hydroxy-3-(4-hydroxyphenyl)-2-[3-(4-hydroxyphenyl)-n-methyl-2-(methylamino)propanamido]propylidene]amino}-4-methylpentylidene)amino]propanoic acid
methyl 2-[(1r,2s,3s)-2-[(1s,5s,6r,7r,7as)-6,7-bis(acetyloxy)-1-(furan-3-yl)-7a-methyl-4-methylidene-2,5,6,7-tetrahydro-1h-inden-5-yl]-3-hydroxy-2,6,6-trimethyl-5-oxocyclohexyl]acetate
1-{3-[1,4-bis(4-hydroxyphenyl)-2,3-dimethylbutyl]-2,4,6-trihydroxyphenyl}-3-(4-methoxyphenyl)propan-1-one
2-{[(6r)-6-[(1s)-1-[(1s,2r,6s,7r,9r,11s,12s,15r,16s)-6-hydroxy-2,16-dimethyl-3-oxo-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadec-4-en-15-yl]ethyl]-4-methyl-2-oxo-5,6-dihydropyran-3-yl]methoxy}propan-2-yl formate
methyl (1s,4as,6s,7r,7as)-6-{[(2e,6e)-8-hydroxy-2,6-dimethylocta-2,6-dienoyl]oxy}-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-carboxylate
(4s)-2-hexanoyl-6-[(3-hexanoyl-2,4-dihydroxy-6-methoxyphenyl)methyl]-3,5-dihydroxy-4-methyl-4-(3-methylbut-2-en-1-yl)cyclohexa-2,5-dien-1-one
methyl (1s,4as,6s,7r,7as)-6-{[(2e)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy}-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-carboxylate
methyl (1s,4as,6s,7r,7as)-6-hydroxy-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2e)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy}methyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-carboxylate
(3s,3ar,4s,6s,6ar,10s,13r,17as)-4-ethyl-1,6,13-trihydroxy-3-[(1r)-1-(1h-indol-3-yl)ethyl]-10,12-dimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,13h-cyclotrideca[d]isoindole-14,17-dione
(1r,4s,5s,6r,9s,10s,13r,14r,15r)-5-formyl-6,14-dihydroxy-5,9-dimethyl-14-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-15-yl acetate
{8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-11-en-13-yl}methyl 2-aminobenzoate
4-ethyl-1,6,13-trihydroxy-3-[1-(1h-indol-3-yl)ethyl]-10,12-dimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,13h-cyclotrideca[d]isoindole-14,17-dione
{6-[3-(hexadecanoyloxy)-2-hydroxypropoxy]-3,4,5-trihydroxyoxan-2-yl}methanesulfonic acid
(1r,2s,3r,4r,4as,8ar)-2-(benzoyloxy)-3-hydroxy-3,4,8,8a-tetramethyl-4-[(1e)-2-(5-oxo-2h-furan-3-yl)ethenyl]-2,4a,5,6-tetrahydro-1h-naphthalen-1-yl benzoate
(1s,2s,6s,7s,9r,11s,13s,14r,15s,16s,17s)-16-hydroxy-4,15-dimethoxy-2,6,14,17-tetramethyl-11-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-3-one
(1r)-1-[(1'r,2s,3'r,8'r,12'e,17'r,18'e,20'z,24'r,25's)-5',13',25'-trimethyl-11',22'-dioxo-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraen-17'-yl]ethyl acetate
1-[(18'e)-5',13',25'-trimethyl-11',22'-dioxo-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraen-17'-yl]ethyl acetate
(1s,2r,5s,6s,13s,14r,16r)-6-(furan-3-yl)-13-hydroxy-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-10-en-14-yl 2-methylpropanoate
1-{3-[(1s,2r,3s)-1,4-bis(4-hydroxyphenyl)-2,3-dimethylbutyl]-2,4,6-trihydroxyphenyl}-3-(4-methoxyphenyl)propan-1-one
(1r,3br,4s,5r,5as,7r,9s,9ar,9br,11as)-7,9-bis(acetyloxy)-1-(furan-3-yl)-5-hydroxy-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
2-hexanoyl-6-[(3-hexanoyl-2,4-dihydroxy-6-methoxyphenyl)methyl]-3,5-dihydroxy-4-methyl-4-(3-methylbut-2-en-1-yl)cyclohexa-2,5-dien-1-one
2-(2,4-dihydroxyphenyl)-3-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-5-hydroxy-8,8-dimethyl-6-(3-methylbut-2-en-1-yl)pyrano[2,3-h]chromen-4-one
6-(furan-3-yl)-13-hydroxy-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-10-en-14-yl 2-methylpropanoate
6-[(1s,13r,14s,17s,19s)-19-(acetyloxy)-10-hydroxy-13,14,18,18-tetramethyl-7-oxo-2-oxa-6-azapentacyclo[11.8.0.0¹,¹⁷.0³,¹¹.0⁴,⁸]henicosa-3(11),4(8),9-trien-6-yl]-2-aminohexanoic acid
13-(acetyloxy)-1-hydroxy-8,12-bis(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl deca-2,4-dienoate
methyl (1s,4as,6s,7r,7as)-6-{[(2e,6s)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy}-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-carboxylate
6-[19-(acetyloxy)-10-hydroxy-13,14,18,18-tetramethyl-7-oxo-2-oxa-6-azapentacyclo[11.8.0.0¹,¹⁷.0³,¹¹.0⁴,⁸]henicosa-3(11),4(8),9-trien-6-yl]-2-aminohexanoic acid
8,9-bis(acetyloxy)-2,6-dihydroxy-3a-(2-hydroxypropan-2-yl)-1,8a-dimethyl-5-methylidene-2h,3h,4h,4ah,6h,7h,8h,9h,10h-cyclohexa[f]azulen-10-yl benzoate
(2s,9r,13s,15s,17s)-16-hydroxy-4,15-dimethoxy-2,6,14,17-tetramethyl-11-{[(2s,4s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-3-one
methyl (4s,5e,6s)-5-ethylidene-4-(2-{[(2e)-6-hydroxy-2,6-dimethylocta-2,7-dien-1-yl]oxy}-2-oxoethyl)-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,6-dihydropyran-3-carboxylate
9-(benzoyloxy)-8-[(benzoyloxy)methyl]-1-isopropyl-5a-methyl-6-oxo-2h,3h,4h,5h,9h,10h,10ah-cyclohepta[e]indene-3a-carboxylic acid
[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-11-en-13-yl]methyl 2-aminobenzoate
(2r,3r)-2-methyl-5-oxooxolan-3-yl (2r,3s,6s,7s,9r)-2-[(2s,5s)-5-(3-hydroxyphenyl)-5-methoxypentan-2-yl]-3,9,11,11-tetramethyl-8-oxo-1-oxaspiro[5.5]undec-4-ene-7-carboxylate
(1r)-1-[(1'r,2s,3'r,8'r,12'e,17'r,18'e,24'r,25's)-5',13',25'-trimethyl-11',22'-dioxo-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraen-17'-yl]ethyl acetate
4-[(3,4-dihydroxy-6-{4-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-6-pentyl-1,3-dioxan-2-yl}-2-methylphenyl)methyl]-5,5-dimethyloxolan-2-one
(1s,3e,6r,7e,9s,11e,13r,14s,16r,17s,18r)-17-ethyl-6,21-dihydroxy-19-[(1r)-1-(1h-indol-3-yl)ethyl]-7,9,16-trimethyl-15-oxa-20-azatetracyclo[11.8.0.0¹,¹⁸.0¹⁴,¹⁶]henicosa-3,7,11,20-tetraene-2,5-dione
1-{2,3-bis[(1e)-2-(2h-1,3-benzodioxol-5-yl)ethenyl]-4-(pyrrolidine-1-carbonyl)cyclobutanecarbonyl}piperidine
C33H36N2O6 (556.2573236000001)
6-{2,8-dihydroxy-3a,6,6,9b,11a-pentamethyl-7,10-dioxo-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthren-1-yl}-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate
(1r,2r,6s,10r,11r,12s,13s,14r,15r)-13-(acetyloxy)-1-hydroxy-8,12-bis(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl (2e,4e)-deca-2,4-dienoate
16-(acetyloxy)-10-hydroxy-2,9,13,17-tetramethyl-7-(4-methyl-2-oxopent-3-en-1-yl)-6-oxo-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-1(20)-ene-17-carboxylic acid
(1r,3r,4r,4as,7s,8as)-4-hydroxy-3,4a,8,8-tetramethyl-4-[2-(2-oxo-5h-furan-3-yl)ethyl]-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-hexahydro-1h-naphthalen-1-yl acetate
(2r,4s,7r,8s,9s,10s,12r,13r,16r,17s,18r)-16-(acetyloxy)-10-hydroxy-2,9,13,17-tetramethyl-7-(4-methyl-2-oxopent-3-en-1-yl)-6-oxo-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-1(20)-ene-17-carboxylic acid
3-ethenyl-5-hydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-octahydronaphtho[2,1-b]pyran-6-yl acetate
(2s)-2-{[(2s)-1-hydroxy-2-{[(2s)-1-hydroxy-3-(4-hydroxyphenyl)-2-[(2s)-3-(4-hydroxyphenyl)-n-methyl-2-(methylamino)propanamido]propylidene]amino}-4-methylpentylidene]amino}propanoic acid
(1s,7z,9s,11z,13r,14s,16r,17s,18r,19s)-17-ethyl-21-hydroxy-19-[(1r)-1-(1h-indol-3-yl)ethyl]-7,9,16-trimethyl-15-oxa-20-azatetracyclo[11.8.0.0¹,¹⁸.0¹⁴,¹⁶]henicosa-7,11,20-triene-2,5,6-trione
methyl (1s,4as,6s,7r,7as)-6-{[(2e,6z)-8-hydroxy-2,6-dimethylocta-2,6-dienoyl]oxy}-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-carboxylate
(1r,2r,6s,7s,8r,10s,11s,12r,14s,16r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-16-(prop-1-en-2-yl)-14-[(1e,3e)-undeca-1,3-dien-1-yl]-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-5-one
(1r,2s,5r,6r,10s,13s,14r,16s)-6-(furan-3-yl)-16-[(1r)-1-hydroxy-2-methoxy-2-oxoethyl]-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl 2-methylpropanoate
5-(acetyloxy)-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl 1-methyl butanedioate
2-methoxy-3-(methoxycarbonyl)-4-(2-oxoheptyl)phenyl 2-hydroxy-4-methoxy-6-(2-oxoheptyl)benzoate
5-formyl-6,14-dihydroxy-5,9-dimethyl-14-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-15-yl acetate
(1s,2r,4r,6s,7s,10r,11s,12s,14r,16s,18r)-12,14-bis(acetyloxy)-6-(furan-3-yl)-1,7,11,15,15-pentamethyl-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-18-yl acetate
(2s)-2-{[(2s)-2-{[(3-{3,4-dihydroxy-5-[1-(c-hydroxycarbonimidoyl)-2-iminoimidazolidin-4-yl]pentyl}-5-hydroxy-6-methyl-1,2,3,6-tetrahydropyrazin-2-yl)(hydroxy)methylidene]amino}-1-hydroxypropylidene]amino}-3-methylbutanoic acid
C23H40N8O8 (556.2968960000001)
2-{[(2e,4e,6e,8e,10e,12e,14e,16e)-1-hydroxy-2-methyl-17-[(4r,5r)-5-methyl-2-[(1e)-2-(1h-pyrrol-2-yl)ethenyl]-4,5-dihydro-1,3-oxazol-4-yl]heptadeca-2,4,6,8,10,12,14,16-octaen-1-ylidene]amino}-3-(c-hydroxycarbonimidoyl)propanoic acid
1-{3-[(1r,2r,3s)-1,4-bis(4-hydroxyphenyl)-2,3-dimethylbutyl]-2,4,6-trihydroxyphenyl}-3-(4-methoxyphenyl)propan-1-one
1-{2,3-bis[2-(2h-1,3-benzodioxol-5-yl)ethenyl]-4-(pyrrolidine-1-carbonyl)cyclobutanecarbonyl}piperidine
C33H36N2O6 (556.2573236000001)